Bristol-Myers Squibb, a global biopharma company, has named Jose Baselga as its director, serving as a member of its science and technology committee, it was reported yesterday.
Presently, Dr Baselga is the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and translational research. He brings more than 30 years of clinical and research experience to his new position on the board, and his career history has seen him serve as president for the American Association for Cancer Research.
Giovanni Caforia, chairman and chief executive officer of BMS, said, 'Jose is an internationally-recognised physician scientist in oncology with deep experience in teaching at leading academic institutions, pioneering research for targeted cancer therapies and treating patients. His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.'
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval